2018 Annual Report


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape

906+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

484North America23Oceania1Africa142Asia15South America241Europe & Israel

Financings

Total 2018 Global Financings

Total Global Financing

$13.3 Billion

 73%

Increase from 2017

Gene & Gene-modified
Cell Therapy

$9.7 Billion

 64%

Increase from 2017

Cell Therapy

$7.6 Billion

 64%

Increase from 2017

Tissue Engineering

$937 Million

 258%

Decrease from 2017

9351702357414814329278425081947723592646392611334796947625937Total Global FinancingsGene and Gene-Modified Cell TherapyCell TherapyTissue Engineering0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m2015201620172018

Total Global Financings by Type

1653224424331913964594890647125094225439941121144865919274715174029071245IPOsFollow-OnsCorporatePartnershipsVenture CapitalPrivatePlacement /PIPES0$500m$1,000m$1,500m$2,000m$2,500m$3,000m$3,500m$4,000m$4,500m$5,000m$5,500m$6,000m2015201620172018
176110331353918944Mergers &Acquisitions0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m$18,000m$20,000m$22,000m$24,000m2015201620172018

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

EOY 2018

Gene Therapy
33.1%58.0%8.8%020406080100120140160180200220Phase IPhase IIPhase III
Gene-Modified
Cell Therapy
43.6%51.9%0020406080100120140160180200Phase IPhase IIPhase III
Cell Therapy
20.2%67.3%12.5%020406080100120140160180Phase IPhase IIPhase III
Tissue Engineering
24.4%48.8%26.8%09101112131415161718192021Phase IPhase IIPhase III